Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $37.67 billion. The enterprise value is $44.16 billion.
| Market Cap | 37.67B |
| Enterprise Value | 44.16B |
Important Dates
The last earnings date was Wednesday, October 28, 2026, before market open.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 147.82 million shares outstanding. The number of shares has increased by 1.49% in one year.
| Current Share Class | 147.82M |
| Shares Outstanding | 147.82M |
| Shares Change (YoY) | +1.49% |
| Shares Change (QoQ) | -0.61% |
| Owned by Insiders (%) | 0.21% |
| Owned by Institutions (%) | 97.91% |
| Float | 147.28M |
Valuation Ratios
The trailing PE ratio is 109.07 and the forward PE ratio is 17.27. Biogen's PEG ratio is 1.84.
| PE Ratio | 109.07 |
| Forward PE | 17.27 |
| PS Ratio | 3.66 |
| Forward PS | 3.54 |
| PB Ratio | 1.99 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.19 |
| P/OCF Ratio | 16.77 |
| PEG Ratio | 1.84 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.38, with an EV/FCF ratio of 21.33.
| EV / Earnings | 127.11 |
| EV / Sales | 4.29 |
| EV / EBITDA | 13.38 |
| EV / EBIT | 18.25 |
| EV / FCF | 21.33 |
Financial Position
The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.95 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 2.28 |
| Debt / FCF | 3.77 |
| Interest Coverage | 7.94 |
Financial Efficiency
Return on equity (ROE) is 1.87% and return on invested capital (ROIC) is 7.36%.
| Return on Equity (ROE) | 1.87% |
| Return on Assets (ROA) | 4.94% |
| Return on Invested Capital (ROIC) | 7.36% |
| Return on Capital Employed (ROCE) | 8.60% |
| Weighted Average Cost of Capital (WACC) | 4.44% |
| Revenue Per Employee | $1.37M |
| Profits Per Employee | $46,333 |
| Employee Count | 7,500 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 1.13 |
Taxes
In the past 12 months, Biogen has paid $97.60 million in taxes.
| Income Tax | 97.60M |
| Effective Tax Rate | 21.93% |
Stock Price Statistics
The stock price has increased by +63.85% in the last 52 weeks. The beta is 0.09, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | +63.85% |
| 50-Day Moving Average | 230.73 |
| 200-Day Moving Average | 203.59 |
| Relative Strength Index (RSI) | 61.50 |
| Average Volume (20 Days) | 1,346,657 |
Short Selling Information
The latest short interest is 5.50 million, so 3.72% of the outstanding shares have been sold short.
| Short Interest | 5.50M |
| Short Previous Month | 5.97M |
| Short % of Shares Out | 3.72% |
| Short % of Float | 3.73% |
| Short Ratio (days to cover) | 4.46 |
Income Statement
In the last 12 months, Biogen had revenue of $10.30 billion and earned $347.50 million in profits. Earnings per share was $2.34.
| Revenue | 10.30B |
| Gross Profit | 7.80B |
| Operating Income | 2.42B |
| Pretax Income | 445.10M |
| Net Income | 347.50M |
| EBITDA | 3.30B |
| EBIT | 2.42B |
| Earnings Per Share (EPS) | $2.34 |
Balance Sheet
The company has $1.30 billion in cash and $7.80 billion in debt, with a net cash position of -$6.50 billion or -$43.95 per share.
| Cash & Cash Equivalents | 1.30B |
| Total Debt | 7.80B |
| Net Cash | -6.50B |
| Net Cash Per Share | -$43.95 |
| Equity (Book Value) | 18.92B |
| Book Value Per Share | 128.03 |
| Working Capital | 3.69B |
Cash Flow
In the last 12 months, operating cash flow was $2.25 billion and capital expenditures -$176.40 million, giving a free cash flow of $2.07 billion.
| Operating Cash Flow | 2.25B |
| Capital Expenditures | -176.40M |
| Depreciation & Amortization | 881.80M |
| Net Borrowing | 623.30M |
| Free Cash Flow | 2.07B |
| FCF Per Share | $14.01 |
Margins
Gross margin is 75.77%, with operating and profit margins of 23.50% and 3.37%.
| Gross Margin | 75.77% |
| Operating Margin | 23.50% |
| Pretax Margin | 4.32% |
| Profit Margin | 3.37% |
| EBITDA Margin | 32.07% |
| EBIT Margin | 23.50% |
| FCF Margin | 20.11% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.49% |
| Shareholder Yield | -1.49% |
| Earnings Yield | 0.92% |
| FCF Yield | 5.50% |
Analyst Forecast
The average price target for Biogen is $268.26, which is 5.28% higher than the current price. The consensus rating is "Buy".
| Price Target | $268.26 |
| Price Target Difference | 5.28% |
| Analyst Consensus | Buy |
| Analyst Count | 36 |
| Revenue Growth Forecast (3Y) | 3.96% |
| EPS Growth Forecast (3Y) | 6.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 2.89 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.89 |
| Piotroski F-Score | 5 |